Tilray Brands, Inc. (TLRY) - 10-K Summary for Fiscal Year Ended May 31, 2026
Business Context and Reporting Period
This Annual Report covers the fiscal year ended May 31, 2026. Tilray Brands, Inc. operates as a global lifestyle consumer products company with four reportable segments: Beverage, Cannabis, Distribution, and Wellness. The company is headquartered in Leamington, Ontario, and New York, with operations spanning North America, Europe, Australia, and Latin America. A key strategic milestone for the period was the transformation of the beverage platform into a global entity through the acquisition of BrewDog assets in the UK, Australia, and the U.S., alongside the acquisition of the Lyphe Group, a UK-based medical cannabis clinic and digital pharmacy platform.
Key Financial Metrics
| Metric (in thousands USD) | Fiscal 2026 | Fiscal 2025 | Change |
|---|---|---|---|
| Net Revenue | $915,454 | $821,309 | +11% |
| Gross Profit | $260,441 | $240,570 | +8% |
| Gross Margin | 28% | 29% | -1% |
| Operating Loss | $(63,027) | $(2,282,705) | Improvement of $2.2B |
| Net Loss | $(105,158) | $(2,181,356) | Improvement of $2.1B |
| Adjusted EBITDA | $61,139 | $55,035 | +11% |
| Cash & Marketable Securities | $234,631 | $256,363 | -8% |
| Working Capital | $433,754 | $408,323 | +6% |
Material Changes vs. Prior Period
- Revenue Growth: Total net revenue increased 11% to $915.5 million. The Distribution segment saw the highest growth at 21% ($327.2M), driven by competitive pricing and product mix. Cannabis revenue grew 8% to $268.3M, primarily due to a 34% increase in international sales, offset by a decline in wholesale cannabis revenue. Beverage revenue grew 6% to $254.0M, including $51.1M from the BrewDog acquisition.
- Profitability Improvement: The significant reduction in Net Loss (from $2.18B to $105M) was primarily driven by the absence of a $2.1 billion non-cash impairment of goodwill and intangible assets recorded in Fiscal 2025. Operating expenses decreased by 87% year-over-year, largely due to lower amortization and the absence of prior-year impairments.
- Segment Margins: Cannabis adjusted gross margin remained stable at 40%. Beverage adjusted gross margin decreased slightly to 37% from 39%, impacted by lower fixed overhead utilization and higher input costs, partially offset by the higher-margin BrewDog business.
- Acquisitions: The company completed the BrewDog Acquisition (UK, Australia, U.S. assets) and the Lyphe Group acquisition in Q4, adding significant international infrastructure and medical cannabis capabilities.
Guidance, Outlook, and Risks
- Regulatory Environment: The U.S. Department of Justice issued an order in April 2026 rescheduling FDA-approved cannabis products and state-licensed medical cannabis from Schedule I to Schedule III. The company is monitoring ongoing legal challenges to this rescheduling. In the U.S., new Farm Bill amendments regarding "total THC" standards for hemp products are scheduled to take effect in November 2026, which may impact the Wellness segment.
- Strategic Outlook: Management remains focused on cost reduction, cash generation, and leveraging the BrewDog platform for global beverage distribution. The company expects to continue optimizing its cost structure and expanding margins.
- Key Risks:
- Regulatory Uncertainty: Changes in cannabis laws in the U.S. and internationally, including potential delays in legalization or adverse regulatory changes, could materially impact operations.
- Competition: Intense competition in both the legal and illicit cannabis markets, as well as the crowded craft beverage sector.
- Financial Covenants: The company maintains debt service and leverage covenants; failure to comply could result in default.
- Goodwill Impairment: While no impairment was recorded in 2026, the company holds $752.4 million in goodwill (primarily Cannabis). Future declines in market capitalization or profitability could trigger additional impairments.
Investor Verification Checklist
- Debt Structure: Verify the terms of the $88 million principal outstanding on the 5.20% Convertible Senior Notes due 2027 and the impact of recent debt-for-equity exchange transactions.
- Acquisition Integration: Assess the integration progress and financial performance of the BrewDog and Lyphe acquisitions, which were completed late in the fiscal year.
- Regulatory Timeline: Monitor the status of the U.S. cannabis rescheduling legal challenges and the implementation of the new "total THC" hemp standards effective November 2026.
- Goodwill Valuation: Review the assumptions used in the qualitative goodwill impairment assessment, particularly regarding the probability of U.S. and EU cannabis legalization.
- Working Capital: Analyze the $87.3 million use of cash in working capital, driven largely by the BrewDog acquisition and inventory build for international growth.